The mortality rate among patients having heart failure (HF) with reduced ejection fraction (EF) following a heart attack has gradually been reduced through the cumulative benefit of medications such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, β-blockers, and mineralocorticoid-receptor antagonists.1,2 However, surviving patients with ischemic cardiomyopathy and HF face a broad spectrum of symptoms, emphasizing the need for new prognostic models to stratify patient subgroups and to develop new therapies. The gene discussed is ACE; the disease is hydrops fetalis.